Home/Pasithea Therapeutics/Daniel Schneiderman

DS

Daniel Schneiderman

Chief Financial Officer

Pasithea Therapeutics

Therapeutic Areas

Neurology Psychiatry RASopathies

Pasithea Therapeutics Pipeline

Drug	Indication	Phase
PAS-004 (MEK Inhibitor)	Neurofibromatosis Type 1 (NF1)	Preclinical
MEK Inhibitor Program	Amyotrophic Lateral Sclerosis (ALS)	Discovery

Leadership Team at Pasithea Therapeutics

Professor Lawrence Steinman, MD, PhD

Tiago Reis Marques, MD, PhD

Chief Executive Officer

Graeme Currie, PhD

Chief Development Officer

View full Pasithea Therapeutics profile